BofA Securities Upgrades Apellis Pharmaceuticals (APLS) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St futures rise as AI stocks catch their breath; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 19 | New: 16
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 19 | New: 16
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad upgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Neutral to Buy with a price target of $85.00 (from $52.00).
For an analyst ratings summary and ratings history on Apellis Pharmaceuticals click here. For more ratings news on Apellis Pharmaceuticals click here.
Shares of Apellis Pharmaceuticals closed at $61.58 yesterday.
You May Also Be Interested In
- DA Davidson Upgrades Franklin Electric (FELE) to Buy
- Camerco Corp. (CCO:CN) (CCJ) PT Lowered to Cdn$180 at Canaccord
- Ecovacs Robotics Co Ltd (603486:CH) PT Lowered to RMB45 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
